Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259572 | 0.96 | HRH4 (0.42) | HRH4HRH3NFKB1NFKB2RELA | |
| SCHEMBL4260026 | 0.94 | HRH4 (0.41) | HRH4HRH3NFKB1NFKB2RELA | |
| SCHEMBL4269566 | 0.93 | TSHR (0.41) | LMNAHRH4HRH3NFKB1NFKB2 | |
| SCHEMBL4266791 | 0.91 | SMN1; SMN2 (0.45) | LMNAHSD17B10DHFRHRH4HRH3 | |
| SCHEMBL4260830 | 0.83 | F2 (0.50) | NFKB1NFKB2RELAMAPTRAB9A | |
| SCHEMBL4264697 | 0.83 | MAOB (0.41) | HRH4HRH3NFKB1NFKB2RELA | |
| SCHEMBL4266993 | 0.83 | POLB (0.40) | HRH4HRH3NFKB1NFKB2RELA | |
| SCHEMBL4260835 | 0.83 | NFKB1 (0.57) | LMNANFKB1NFKB2RELAMAPT | |
| SCHEMBL4274497 | 0.76 | HTT (0.54) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4259574 | 0.70 | APP (0.50) | LMNANFKB1NFKB2RELAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | LU ZHIMIN | 2009-03-26 | — | — | US | claimed |
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | LU ZHIMIN | 2009-03-26 | — | — | US | disclosed |
| CN-101269077-A | Use of NF-kB inhibitors for treating retroviral infections | ZHIMIN LU (CN) | 2008-09-24 | — | — | CN | disclosed |
| CN-100418532-C | NF-kB compound inhibitor for treating various diseases | ZHIMIN LU (CN) | 2008-09-17 | — | — | CN | disclosed |
| CN-101239056-A | Use of NF-kB inhibitors for treating various diseases | ZHIMIN LU (CN) | 2008-08-13 | — | — | CN | disclosed |
| CN-1709259-A | Use of NF-kB inhibitors in the treatment of various diseases | LU ZHIMIN (CN) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | RELA, NFKBIA, NFKB1 | LMNA 2716/4885HTT 3989/4885HSD17B10 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.